Announcements
Announcement to Permit Competitive Conduct by Officers
Date of the board of directors resolution: Jun 27, 2019 Name and title of the managerial officer with permission to engage in competitive conduct: Director Tamon Tseng, Representative of Yi Tai …
Announcement on Re-election of Board of Directors at the 2019 Annual General Meeting
Date of occurrence of the change: Jun 27, 2019 Appointment of or changed personnel (juristic-person director, juristic-person supervisor, independent director, natural-person director or natural-person supervisor): juristic-person director, independent director Title, …
Announcement of Resolution Items from 2019 Annual General Meeting
Date of the shareholders’ meeting: Jun 27, 2019 Important resolutions (1)profit distribution/deficit compensation: Resolution on 2018 Deficit Compensation Important resolutions (2) amendments of the company charter: Resolution of amendment of …
Clarification on the news article by internet media on Jun 21,2019
Date of occurrence of the event: Jun 21, 2019 Company name: OBI Pharma, Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: None …
Company Chairman Mr. Michael Chang and other five executives received an acquittal for insider trading case by Taiwan Shilin District Court
Parties to the legal matter: Michael Chang (Chairman); Youe-Kong Shue (Former Vice Chairman); Amy Hung (General Manager); Tony Yu (Chief Science Officer); Jon-Jin Liao (Former Medical Business Director) Name of …
Clarification on new article by Economy Daily News dated Jun 16, 2019
Date of occurrence of the event: Jun 16, 2019 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: N/A …
OBI-888 completes Phase I safety evaluation and demonstrates its safety and tolerability with no major concerns
Date of occurrence of the event: Jun 15, 2019 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: N/A …
Announcement of the company’s cash capital increase and base date
Date of occurrence of the event: Jun 14, 2019 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): head office Reciprocal shareholding ratios: N/A …
Board of directors of the company waived subscription rights exceeding half of the total subscribable shares. Shares to be subscribed by designated persons
Date of occurrence of the event: Jun 10, 2019 Reason for the forfeiture of subscription rights by the directors and supervisors: Overall investment strategy and financial planning considerations. Names of …
Letter received from National Medical Products Administration (NMPA) of China regarding Adagloxad Simolenin (OBI-822) Phase III clinical study to be resubmitted after supplementation
Date of occurrence of the event: May 06, 2019 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: N/A …